← Leaderboards
Jessica Fortin
Purdue University
$1,059,319
Attributed
$1,059,319
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $346K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,059,319 · 2
By mechanism
K08$657,093 · 1
R21$402,226 · 1
Top collaborators
No co-investigators on record.
Most similar at Purdue University
Same institution · by research overlap
- Kathleen M Hill Gallant$2,239,947
- Michael Keith Wendt$4,884,793
- Tzu-Wen Liu Cross$101,808
- Rahim Rahimi$101,808
- Mohit Singh Verma$101,808
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposPropertyDoseNeurofibrillary TanglesPermeabilityPreclinical StudyHyperphosphorylated TauDrug DiscoveryNerve DegenerationMetabolismAbsorptionNeurotoxicCytoprotectionPharmacokinetics And PharmacodynamicsProtein IsoformsCytotoxicityBrainDrug DevelopmentImpaired CognitionIn VitroCell DeathLinkBlood - Brain Barrier AnatomyRecombinants
Grant awards (6)
Small molecule inhibitors of hyperphosphorylated tau aggregation in Alzheimer's disease: lead optimization, and proof of concept in a rodent model$164,430
K08 · FY2025 · AG · contact PI
Small molecule inhibitors of hyperphosphorylated tau aggregation in Alzheimer's disease: lead optimization, and proof of concept in a rodent model$164,221
K08 · FY2024 · AG · contact PI
Small molecule inhibitors of hyperphosphorylated tau aggregation in Alzheimer's disease: lead optimization, and proof of concept in a rodent model$164,221
K08 · FY2023 · AG · contact PI
Small molecule inhibitors of hyperphosphorylated tau aggregation and cytotoxicity for the development of Alzheimerâs therapeutics$181,738
R21 · FY2022 · AG · contact PI
Small molecule inhibitors of hyperphosphorylated tau aggregation in Alzheimer's disease: lead optimization, and proof of concept in a rodent model$164,221
K08 · FY2022 · AG · contact PI
Small molecule inhibitors of hyperphosphorylated tau aggregation and cytotoxicity for the development of Alzheimerâs therapeutics$220,488
R21 · FY2021 · AG · contact PI